Albumin is the most abundant protein in human blood plasma, and the measurement of serum albumin level is one of the most informative tests available for assessing liver health, nutritional status, and overall physiological reserve. Unlike the liver enzymes ALT and AST, which measure hepatocellular damage, albumin measures the liver’s synthetic function — its capacity to produce proteins. This makes albumin a fundamentally different kind of liver test: not a marker of inflammation or injury, but a marker of function. When the liver can no longer synthesize albumin at adequate rates, whether due to chronic disease, cirrhosis, or acute liver failure, the consequences extend far beyond the blood result itself — affecting fluid balance, drug transport, immune function, and overall clinical prognosis. Understanding albumin in the context of liver function requires knowing what albumin does, what lowers it, how it fits into the clinical picture of liver disease, and what its level tells us about prognosis and the need for intervention.
The serum albumin test is included in most comprehensive metabolic panels and liver function tests, typically reported alongside total protein. Normal serum albumin is 35–50 g/L (3.5–5.0 g/dL) in most laboratories, with values below 35 g/L (3.5 g/dL) classified as hypoalbuminaemia. The interpretation of a low albumin, however, requires careful clinical correlation: albumin is reduced not only by liver disease but by malnutrition, nephrotic syndrome, protein-losing enteropathy, severe systemic inflammation, and major illness of almost any kind. This non-specificity means that an isolated low albumin — without other liver test abnormalities, without clear liver disease, and without an appropriate clinical explanation — requires investigation of these non-hepatic causes before concluding that the liver’s synthetic function is impaired. In the setting of established chronic liver disease or cirrhosis, however, a falling albumin carries direct clinical significance, reflecting deteriorating synthetic function and correlating with increasing risk of complications including ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, and liver-related mortality.
What Albumin Does in the Body
Albumin performs several critical physiological functions that explain why its reduction in liver disease produces clinical consequences across multiple organ systems. Its most important role in the context of liver disease is maintaining plasma oncotic pressure — the osmotic pressure gradient across capillary walls that keeps fluid within the intravascular compartment. Albumin constitutes approximately eighty percent of the plasma oncotic pressure in normal physiology, and when albumin falls significantly (typically below 25–28 g/L), the reduced oncotic pressure allows fluid to leak from blood vessels into surrounding tissue and body cavities. In patients with cirrhosis and portal hypertension, this mechanism — combined with elevated portal pressures and sodium retention from activated renin-angiotensin-aldosterone (RAAS) and sympathetic nervous systems — produces ascites (fluid in the peritoneal cavity), peripheral oedema, and pleural effusions that are cardinal features of decompensated liver disease. The article on abdominal swelling and liver disease covers how ascites presents clinically and what it indicates about liver function status.
Beyond oncotic pressure, albumin is the primary carrier protein for a wide range of substances in the circulation — including free fatty acids, bilirubin, calcium, many drugs, and hormones. When albumin is low, the distribution and bioavailability of these substances changes: drugs that are normally highly albumin-bound (phenytoin, warfarin, furosemide, diazepam, many antibiotics) have increased free fractions, potentially producing enhanced pharmacological effects or toxicity at doses that would be well-tolerated with normal albumin levels. This has direct prescribing implications — patients with significant hypoalbuminaemia from liver disease or other causes require careful drug dosing review, and standard weight-based doses may produce unpredictable effects. Additionally, albumin has anti-inflammatory, antioxidant, and binding properties that contribute to its role in systemic physiology beyond simple protein mass — a partially albumin-infused cirrhotic patient benefits from these non-oncotic properties as well, which is one rationale for human albumin solution (HAS) infusion in large-volume paracentesis for ascites management and in spontaneous bacterial peritonitis (SBP) treatment to reduce renal impairment risk.
Albumin in Chronic Liver Disease and Cirrhosis
In chronic liver disease, the albumin level is one of the most important prognostic markers available, incorporated into the Child-Pugh scoring system alongside bilirubin, INR/prothrombin time, ascites severity, and hepatic encephalopathy grade. The Child-Pugh score divides patients into Class A (well-compensated cirrhosis, score 5–6, relatively preserved synthetic function), Class B (significant functional compromise, score 7–9), and Class C (decompensated cirrhosis, score 10–15, poor synthetic function, high short-term mortality risk). Within this score, albumin below 28 g/L contributes to Class C classification and is associated with median survival measured in months rather than years in the absence of liver transplantation. The threshold of albumin below 28 g/L is also frequently used as a criterion for increased monitoring frequency, specialist hepatology referral, and early transplant assessment discussion in chronic liver disease management.
The trend of albumin over time is more clinically informative than any single value. A patient with cirrhosis whose albumin has been stable at 32–34 g/L for two years, then falls to 28 g/L over six months, is showing a different clinical picture than a patient who has always had an albumin of 28 g/L due to nutritional factors. Serial albumin measurement — typically every three to six months in established cirrhosis — allows clinicians to detect this deterioration early and intervene before decompensation occurs: optimizing nutrition, reviewing medications that might impair hepatic protein synthesis, screening for evolving complications such as hepatocellular carcinoma, and initiating transplant evaluation while the patient’s performance status still permits surgery. Nutritional supplementation — specifically branched-chain amino acid (BCAA) supplementation and overnight fasting avoidance — has evidence for improving albumin levels and muscle mass in cirrhotic patients with sarcopenia (muscle wasting), and is an underutilised adjunct in cirrhosis management that can improve quality of life and reduce hospitalisation. For an understanding of how liver synthetic failure connects to visible clinical signs, the article on easy bruising and liver synthetic failure provides complementary clinical context.
Non-Hepatic Causes of Low Albumin
Because albumin is synthesized by the liver but lost or diluted through several non-hepatic mechanisms, a low albumin does not automatically imply liver disease — and distinguishing hepatic from non-hepatic hypoalbuminaemia is an important part of interpreting the result. Malnutrition is a common cause of reduced albumin, particularly in older adults, hospitalised patients, and those with chronic illness; albumin below 35 g/L in a cachectic patient without other liver test abnormalities should prompt nutritional assessment rather than liver investigation. Nephrotic syndrome — the renal condition defined by massive protein loss in the urine (proteinuria greater than 3.5 g per day), hypoalbuminaemia, oedema, and hyperlipidaemia — can produce albumin values as low as 10–15 g/L, far lower than most hepatic causes, and is identified by urinalysis showing heavy proteinuria and twenty-four-hour urine protein measurement. Protein-losing enteropathy — abnormal intestinal protein loss in conditions such as inflammatory bowel disease, lymphangiectasia, constrictive pericarditis, and some malignancies — produces low albumin with low total protein but without heavy proteinuria, and requires intestinal imaging or faecal alpha-1-antitrypsin testing to diagnose.
Systemic inflammation (sepsis, major trauma, surgery, burns, critical illness) produces rapid, acute falls in serum albumin through a combination of reduced synthesis, redistribution to extravascular compartments, and dilution from intravenous fluid administration. In the intensive care setting or acutely hospitalized patients, an albumin of 25–30 g/L is common and largely reflects acute phase response rather than intrinsic synthetic failure — the same patient’s albumin may return to normal within weeks of recovery from the acute illness. This acute inflammation-related hypoalbuminaemia is one reason why albumin is a less reliable acute marker of liver function than prothrombin time (PT/INR), which responds to the liver’s synthetic capacity for clotting factors and is less affected by inflammation per se. Pregnancy physiologically reduces albumin by five to ten g/L due to haemodilution from expanded plasma volume, making pregnancy-specific reference ranges necessary when interpreting albumin in pregnant patients. Understanding that albumin reduction in any of these contexts does not indicate liver failure prevents unnecessary concern about liver synthetic function and directs investigation toward the true cause. The article on fatigue in the context of liver disease addresses the clinical overlap between hepatic and non-hepatic explanations for the same symptom.
Frequently Asked Questions About Albumin and Liver Function
My albumin is low but my ALT and AST are normal — does that mean my liver is failing?
Not necessarily. A low albumin with normal ALT, AST, ALP, and GGT should prompt investigation of non-hepatic causes first — particularly malnutrition, nephrotic syndrome (check urinalysis for heavy protein), systemic inflammation, and protein-losing enteropathy. Hepatic synthetic failure sufficient to lower albumin substantially would almost always be accompanied by other markers of liver disease, particularly elevated bilirubin and prolonged PT/INR. An isolated low albumin in an otherwise healthy-appearing individual without known liver disease is more likely nutritional or extra-hepatic in origin. That said, if you have known risk factors for liver disease — significant alcohol use, obesity with metabolic syndrome, family history of liver disease — a low albumin warrants further investigation including liver imaging and a full liver function panel to establish whether early cirrhosis is contributing. The combination of low albumin and elevated bilirubin in the context of any suspected liver condition should be reviewed by a clinician without delay, as it may indicate significant hepatic synthetic impairment.
How is albumin used in liver transplant assessment?
Albumin is one of the five variables in the Child-Pugh scoring system for cirrhosis, which remains widely used for assessing surgical risk and liver function reserve in transplant candidates and non-transplant surgical patients with liver disease. Low albumin (below 28 g/L) contributes to Child-Pugh Class C designation, which identifies patients with the poorest short-term prognosis and highest urgency for transplant consideration. Albumin below 28 g/L is also specifically associated with increased perioperative risk for any surgery in cirrhotic patients — reduced drug binding, increased infection risk, impaired wound healing, and fluid management challenges. The MELD score — the primary tool for transplant priority listing in the United States — does not directly include albumin but incorporates bilirubin, INR, and creatinine; however, the addition of serum sodium to produce the MELD-Na score, and ongoing research into MELD 3.0 incorporating albumin, reflects growing recognition that albumin adds predictive value beyond the traditional MELD variables. In the monitoring of patients on the transplant waiting list, serial albumin trend — alongside MELD-Na score, occurrence of decompensation events, and performance status — informs the urgency and timing of transplant placement. Understanding how albumin connects with the full clinical picture of advanced liver disease, including the digestive warning signs that indicate worsening liver function, helps patients and families understand the significance of results as they change over time.
Sources: NIDDK — Liver Disease · AASLD — Liver Disease Guidelines · Mayo Clinic — Albumin Test
Albumin Infusion in Liver Disease — When and Why
Human albumin solution (HAS) intravenous infusion is an established component of liver disease management in several specific clinical contexts, supported by high-quality randomised controlled trial evidence. In large-volume paracentesis — the drainage of large amounts of ascitic fluid (typically more than five litres) from the peritoneal cavity — albumin infusion at 6–8 g per litre of ascites drained prevents post-paracentesis circulatory dysfunction (PPCD), a haemodynamic complication characterized by a compensatory increase in plasma renin activity, vasodilation, and renal impairment that can precipitate acute kidney injury and accelerate liver decompensation. The EASL (European Association for the Study of the Liver) guidelines and AASLD guidelines both recommend albumin infusion after large-volume paracentesis as standard of care. Without albumin replacement, PPCD occurs in approximately sixty to eighty percent of patients undergoing large-volume paracentesis, and carries significant short-term risk; with albumin, this falls dramatically. In spontaneous bacterial peritonitis (SBP) — the bacterial infection of ascitic fluid that develops in approximately ten percent of cirrhotic inpatients — albumin infusion at 1.5 g/kg on diagnosis and 1 g/kg at day three reduces hepatorenal syndrome incidence from thirty to ten percent and reduces ninety-day mortality from approximately thirty to ten percent, according to the landmark Sort et al. trial. This survival benefit makes albumin infusion in SBP one of the most impactful interventions in hepatology, and it is standard of care in guidelines worldwide.
The ATTIRE (Artificial Intelligence Targeting of Albumin for Inpatients) and PILOT trials investigated whether systematic targeting of albumin to levels above 30 g/L in all hospitalised cirrhotic patients improved outcomes beyond the established indications. The ATTIRE trial — a large UK multicentre randomised controlled trial — found that targeted albumin infusion to maintain levels above 30 g/L in hospitalised cirrhotic patients did not reduce new infections, renal dysfunction, or mortality compared to standard care. This important finding clarified that blanket albumin infusion for all cirrhotic inpatients is not evidence-based, and that the established indications (large-volume paracentesis, SBP) remain the settings where albumin infusion has proven clinical benefit. Outside these specific indications, the management of hypoalbuminaemia in liver disease focuses on addressing the underlying hepatic synthetic dysfunction through treatment of the liver disease itself, nutritional optimization, and management of precipitating factors — rather than exogenous albumin replacement. Patients understanding these nuances can engage more meaningfully in conversations about their treatment plans. The clinical context of how advanced liver disease creates the complications that require these interventions is addressed in the article on abdominal swelling as a sign of advanced liver disease.
Albumin, Sarcopenia, and Nutrition in Chronic Liver Disease
The relationship between albumin, nutritional status, and muscle mass in chronic liver disease is clinically important and often insufficiently addressed in standard management. Cirrhotic patients have a substantially elevated resting energy expenditure — the liver’s failure to efficiently produce energy from glycogen stores (glycogen depletion in cirrhosis) means the body increasingly catabolizes muscle protein for gluconeogenesis, producing progressive sarcopenia (loss of skeletal muscle mass and function). Sarcopenia is present in thirty to seventy percent of cirrhotic patients and is an independent predictor of mortality, increased waiting list mortality, higher post-transplant complications, and reduced quality of life — making it arguably the most underrecognised and undertreated complication of cirrhosis. Serum albumin falls in sarcopenic cirrhosis both because of reduced hepatic synthetic capacity and because reduced dietary protein intake (often driven by anorexia, early satiety from ascites, and protein avoidance misconceptions) further limits substrate for albumin synthesis.
Nutritional interventions with evidence in cirrhosis include: late evening snack (providing thirty to forty grams of carbohydrate before sleep to prevent overnight gluconeogenesis-driven muscle catabolism), branched-chain amino acid (BCAA) supplementation (improving nitrogen balance and reducing hepatic encephalopathy episodes in randomised trials), adequate protein intake (1.2–1.5 g/kg body weight daily, contrary to the outdated advice of protein restriction — protein restriction is now recognised to worsen sarcopenia and is indicated only in overt acute encephalopathy episodes, not as chronic management), and avoiding prolonged fasting periods longer than three to four hours. These interventions can stabilise or modestly improve albumin levels in malnourished cirrhotic patients and improve muscle mass on computed tomography assessment — with clinical benefits in terms of reduced complications and improved transplant eligibility. The interaction between liver synthetic failure, reduced albumin, and the symptoms that patients experience — including the fatigue that is often the earliest and most persistent complaint — connects the blood test result to the lived experience of chronic liver disease.
Albumin in Acute Liver Failure and Prothrombin Time
In acute liver failure — where the liver is losing function rapidly over days rather than months or years — albumin measurement has different clinical utility than in chronic liver disease. Because albumin has a half-life of approximately twenty days in the circulation, acute hepatic synthetic failure does not lower albumin rapidly; a patient who develops acute liver failure over a period of one to two weeks may still have a relatively normal albumin even as other synthetic markers (PT/INR, clotting factors) deteriorate rapidly, since those factors have half-lives measured in hours to days. Prothrombin time (PT) and INR are therefore far more sensitive to acute synthetic failure than albumin, responding within twenty-four to seventy-two hours of significant hepatocyte loss and forming a more immediate measure of how urgently the situation is deteriorating. This is why the King’s College Criteria for acute liver failure prognosis includes INR rather than albumin as a central variable, and why INR is measured daily in acute liver failure monitoring while albumin may be checked less frequently.
The complementarity of albumin and prothrombin time in liver disease assessment represents an important principle: they measure different time scales of synthetic function. PT/INR responds to acute deterioration within hours, making it the go-to marker for assessing the trajectory of acute disease. Albumin reflects the slower decline of synthetic function over weeks to months, making it the more informative marker for tracking chronic disease progression. Combining both provides a more complete picture of synthetic reserve: a patient with cirrhosis and albumin of 26 g/L and INR of 1.8 has significant chronic synthetic impairment; if their INR then rises acutely to 3.5 in the setting of a septic episode, this superimposed acute failure on chronic impairment — acute-on-chronic liver failure (ACLF) — is a distinct and high-risk clinical syndrome requiring immediate escalation, specialist care, and in severe cases emergency transplant evaluation. Understanding the distinction between these two markers — and why they behave differently in different phases of liver disease — is essential for interpreting liver function tests as an evolving clinical story rather than isolated data points. The article on easy bruising and clotting factor production explains the clinical consequences of prolonged PT/INR from a patient-facing perspective.
Taken together, albumin, prothrombin time, bilirubin, ALT, AST, ALP, and GGT constitute the core liver function panel that — when interpreted as a whole, in temporal sequence, and in the context of clinical findings and imaging — provides the most complete laboratory assessment of hepatic health available without invasive testing. Albumin’s particular contribution to this panel — measuring the liver’s foundational capacity to produce the protein that underpins plasma volume, drug transport, oncotic pressure, and systemic physiology — makes it an irreplaceable component of any serious liver function assessment, from the first detection of liver disease through the monitoring of its progression and the planning of its definitive treatment.
For patients living with chronic liver disease — whether newly diagnosed with compensated cirrhosis or managing decompensated disease on the transplant waiting list — serum albumin is not just a number on a blood result but a tangible reflection of how well the liver is keeping up with its most fundamental daily task: producing the protein on which so much else depends. Asking your clinical team what your albumin trend has been over time, whether nutrition and sarcopenia have been specifically assessed, and what target levels are being monitored for transplant eligibility discussions are all appropriate and important questions for patients to raise at clinic appointments. The interconnection between albumin, ascites, fatigue, drug tolerability, and infection risk means that this one number connects to nearly every aspect of day-to-day life with advanced liver disease.
My husband has cirrhosis and his albumin has been dropping for the past year. His hepatologist mentioned transplant but we didn’t fully understand why albumin mattered for that decision until reading this. The Child-Pugh explanation and how albumin below 28 g/L affects prognosis was very clearly explained. Thank you.
Diane, thank you for sharing that — I hope this article provides some useful context for those conversations with your husband’s hepatology team. A few practical points that might help: ask about the trend in his albumin over time (not just the current number), ask whether nutritional assessment and sarcopenia screening have been done, and ask specifically what MELD-Na score thresholds are being targeted for transplant listing. These questions are entirely appropriate and your hepatology team should be able to answer them in a way that helps you understand where things stand.
The distinction between albumin and PT/INR in acute vs chronic liver failure is something I’ve seen confused in clinical practice. The point that albumin takes weeks to fall while INR can rise within hours — and why that means INR is used for acute liver failure scoring — is one of those concepts that should be taught more clearly in medical education.